ZX-29

SKU: orb1308910

Description

ZX-29

Research Area

Cardiovascular Research, Cell Biology, Signal Transduction

Key Properties

• CAS Number: 2254805-62-2
• MW: 518.03
• Purity: 98.32%
• Formula: C₂₃H₂₈ClN₇O₃S
• SMILES: COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCN(C)CC1
• Target: Autophagy,ALK,Apoptosis
• Solubility: DMSO:42.5 mg/mL (82.04 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.86 mM)

Bioactivity

• Target IC50:
  ALK:2.1 nM |ALK (G1202R):3.9 nM |ALK (F1196M):1.3 nM
• In Vivo:
  In a mouse xenograft model, ZX-29 treatment suppresses tumor growth.
• In Vitro:
  ZX-29 dose-dependently inhibits colony formation of NCI-H2228 cells. With an increase in ZX-29 concentration, the cell density decreased gradually, and the cells lost their normal morphology and become sharp and slender. In NCI-H2228 cells, ZX-29 (10 nM; 0-48 hours) inhibits the proliferation of and arrests the cells in G1 phase. ZX-29 (0-81 nM; 24-72 hours) treatment resulted in a decrease in the viability with time and dose. ZX-29 (10 nM; 24 hours) treatment causes typical signs of autophagy and the formation of autophagosomes and enhances the expression level of LC3 and Beclin1. ZX-29 (20 nM; 0-48 hours) treatment significantly increases the mRNA level of CHOP.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Resistance, reticulum, p-STAT3, ZX 29, ZX29, ZX-29, ALK tyrosine kinase receptor, ALK L1196M, ALK G1202R, ALK, Anaplastic lymphoma kinase (ALK), Anaplastic lymphoma kinase, antitumor, Apoptosis, Autophagy, arrest, Bcl-2, caspase-3, Cluster of differentiation 246, CD246, CHOP, endoplasmic, ERS, Inhibitor, p-Akt, inhibit

Compound Identifiers

PubChem CID

142497299